Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers This phase III randomized trial ...
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...
Following is a transcript of their remarks: Rugo: Hello. I'm Hope Rugo, a professor of medicine and director of Breast Oncology in Clinical Trials Education at the University of California San ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results